Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-FAPi
- Development stage
- Unknown
- Lead developer
- Ion Beam Applications
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
211At-FAPi is an alpha-emitting radiopharmaceutical currently in development for the treatment of triple-negative breast cancer (TNBC). Developed by the ACCELERATE consortium under the Innovative Health Initiative (IHI), the compound consists of the alpha-particle emitting isotope astatine-211 (211At) conjugated to a fibroblast activation protein inhibitor (FAPi) ligand. It is designed to target Fibroblast Activation Protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment. By delivering high-linear energy transfer (LET) alpha radiation directly to FAP-positive stromal cells, 211At-FAPi aims to induce potent DNA double-strand breaks in the tumor microenvironment, potentially overcoming the resistance and poor prognosis associated with stroma-rich tumors like TNBC. The program is currently in co-clinical and Phase I development stages.
- Other names
- [211At]At-FAPiastatine-211-labeled FAP inhibitorastatine211-labeled FAP inhibitorastatine 211-labeled FAP inhibitor211At-FAPi compound
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 211At-FAPi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-FAPi.